Clinical effect of deanxit on female menopause functional dyspepsia

Abstract

Objective To investigate the clinical effect of deanxit on treatment of functional dyspepsia in women. Methods Forty-six patients with menopausal functional dyspepsia treated with mosapride combined with rabeprazole were enrolled (control group) by random number table method, and 46 patients with functional dyspepsia treated with deanxit, mosaride and rabeprazole were enrolled as the observation group. Hamiltonian anxiety scale (HAMA) score, and Hamilton depression (HAMD) score and adverse reactions were compared between the two groups before and after treatment. Results There was no significant difference in HAMA score or HAMD score between the two groups before treatment (P>0.05). After treatment, the HAMA score (5.27±1.42) and the HAMD score (5.69±1.38) were significantly higher in the observation group than those in the control group (15.23±2.33) and the HAMD score (13.74±3.09). During the course of treatment, the incidence of adverse reactions in the observation group (2.17%) was significantly lower than that in the control group (13.04%). The total effective rate (97.83%) in the observation group was significantly higher than that in the control group (84.78%), the differences were significant(P<0.05). Conclusions Deanxit has significant clinical effect on female menopausal functional dyspepsia, which can effectively relieve and eliminate the symptoms of the patients, reduce the incidence of adverse reactions and improve the total effective rate of treatment. Deanxit has important guarantee for the physical health of patients with menopausal functional dyspepsia, so it is worthy of clinical application. Key words: Deanxit; Female; Menopausal functional dyspepsia; Mosapride; Rabeprazole